Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.

Journal: The lancet. Healthy longevity
PMID: 36098037

Abstract

BACKGROUND: In Japan, docetaxel, a cytotoxic monotherapy, is the standard drug administered to older patients with advanced non-small-cell lung cancer (NSCLC). Carboplatin plus nab-paclitaxel has shown a high objective response rate in patients with squamous histology and was suggested to improve overall survival in patients aged 70 years and older. The CAPITAL trial aimed to assess the safety and efficacy of carboplatin plus nab-paclitaxel versus docetaxel as first-line therapy for patients aged 70 years and older with advanced squamous NSCLC.

Authors

  • Yoshihito Kogure
    Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan. Electronic address: yoshihito.kogure@nnh.go.jp.
  • Shunichiro Iwasawa
    Department of Respirology, Chiba University Hospital, Chiba, Japan; Chugai Pharmaceutical, Tokyo, Japan.
  • Hideo Saka
    Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Yoichiro Hamamoto
    National Hospital Organization Nishisaitama-Chuo National Hospital, Tokorozawa, Japan.
  • Akiko Kada
    Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Hiroya Hashimoto
    Core Laboratory, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Shinji Atagi
    Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
  • Yuichi Takiguchi
    Department of Medical Oncology, Chiba University Hospital, Chiba, Japan.
  • Noriyuki Ebi
    Department of Respiratory Oncology, Iizuka Hospital, Fukuoka, Japan.
  • Akira Inoue
    Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan.
  • Takayasu Kurata
    Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan.
  • Isamu Okamoto
    Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Masafumi Yamaguchi
    Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Toshiyuki Harada
    Center for Respiratory Diseases, Japan Community Healthcare Organization, Hokkaido Hospital, Sapporo, Japan.
  • Masahiro Seike
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
  • Masahiko Ando
    Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
  • Akiko M Saito
    Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Kaoru Kubota
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
  • Mitsuhiro Takenoyama
    Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Takashi Seto
    Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
  • Nobuyuki Yamamoto
    Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University, Wakayama, Japan.
  • Akihiko Gemma
    Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

Keywords

External Resources

Popular Topics
Recent Journals